Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Evusheld
|
| gptkbp:activities |
neutralizes SARS-Co V-2
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
gptkb:cilgavimab
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:temple
|
| https://www.w3.org/2000/01/rdf-schema#label |
tixagevimab
|
| gptkbp:indication |
pre-exposure prophylaxis
|
| gptkbp:is_used_for |
COVID-19 prevention
|
| gptkbp:marketed_as |
gptkb:Evusheld
|
| gptkbp:targets |
gptkb:spike_protein_of_SARS-Co_V-2
|